Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus
作者
Jie Li,Joanne Kimiko Liu,Angela Chau,S. Van Der Linden,Pei‐Chien Tsai,Akito Nozaki,Philip Vutien,Haruki Uojima,Hidenori Toyoda,Takashi Honda,Huy N. Trinh,Hiroshi Abe,Toru Ishikawa,Masanori Atsukawa,Tsunamasa Watanabe,Kunihiko Tsuji,Jia Hao Law,Koichi Takaguchi,Ei Itobayashi,Sebastián Marciano
BR rates were similar with ETV and TAF, while VR and CR were higher with TAF, although the difference was modest (<5% overall, 7%-9% in high HBV DNA or ALT groups). Antiviral selection between TAF vs ETV should be based mainly on cost, side effect profile, and patient preference.